Synergy CHC Corp. (Uplisting) (SNYR) Competitors $4.07 -0.08 (-1.93%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends SNYR vs. CKPT, IPHA, ADAP, PBYI, BMEA, CDTX, STRO, FATE, TCRX, and INMBShould you be buying Synergy CHC Corp. (Uplisting) stock or one of its competitors? The main competitors of Synergy CHC Corp. (Uplisting) include Checkpoint Therapeutics (CKPT), Innate Pharma (IPHA), Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Biomea Fusion (BMEA), Cidara Therapeutics (CDTX), Sutro Biopharma (STRO), Fate Therapeutics (FATE), TScan Therapeutics (TCRX), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Synergy CHC Corp. (Uplisting) vs. Checkpoint Therapeutics Innate Pharma Adaptimmune Therapeutics Puma Biotechnology Biomea Fusion Cidara Therapeutics Sutro Biopharma Fate Therapeutics TScan Therapeutics INmune Bio Checkpoint Therapeutics (NASDAQ:CKPT) and Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation. Do analysts rate CKPT or SNYR? Checkpoint Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 277.36%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Checkpoint Therapeutics is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CKPT or SNYR more profitable? Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Synergy CHC Corp. (Uplisting) N/A N/A N/A Do institutionals and insiders believe in CKPT or SNYR? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer CKPT or SNYR? Checkpoint Therapeutics received 180 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% Synergy CHC Corp. (Uplisting)N/AN/A Does the media prefer CKPT or SNYR? In the previous week, Checkpoint Therapeutics had 1 more articles in the media than Synergy CHC Corp. (Uplisting). MarketBeat recorded 1 mentions for Checkpoint Therapeutics and 0 mentions for Synergy CHC Corp. (Uplisting). Checkpoint Therapeutics' average media sentiment score of 0.28 beat Synergy CHC Corp. (Uplisting)'s score of 0.00 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Checkpoint Therapeutics Neutral Synergy CHC Corp. (Uplisting) Neutral Which has better valuation & earnings, CKPT or SNYR? Synergy CHC Corp. (Uplisting) has lower revenue, but higher earnings than Checkpoint Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$100K1,552.79-$51.85M-$1.84-1.73Synergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/A SummaryCheckpoint Therapeutics beats Synergy CHC Corp. (Uplisting) on 9 of the 10 factors compared between the two stocks. Get Synergy CHC Corp. (Uplisting) News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHC Corp. (Uplisting)Medicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$35.42M$1.22B$15.55B$9.11BDividend YieldN/AN/A2.85%4.00%P/E RatioN/A21.3917.2713.22Price / SalesN/A5.743.8776.05Price / CashN/A9.9815.7932.90Price / BookN/A2.046.044.58Net IncomeN/A-$53.10M$600.77M$224.84M7 Day Performance-12.66%0.29%1.37%2.37%1 Month Performance-9.56%-0.38%1.97%4.40%1 Year PerformanceN/A-5.93%7.06%20.11% Synergy CHC Corp. (Uplisting) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC Corp. (Uplisting)N/A$4.07-1.9%N/AN/A$35.42MN/A0.0040Gap UpCKPTCheckpoint Therapeutics3.6288 of 5 stars$3.20+1.3%$12.00+275.0%+72.8%$156.27M$47,000.00-1.7410Positive NewsIPHAInnate Pharma3.3275 of 5 stars$1.84+4.0%$11.50+525.0%-35.2%$152.36M$24.85M0.00220News CoveragePositive NewsADAPAdaptimmune Therapeutics2.3764 of 5 stars$0.60-4.0%$2.79+368.5%-17.5%$152.25M$175.04M-2.70449Short Interest ↑PBYIPuma Biotechnology4.0217 of 5 stars$3.08-6.9%$7.00+127.3%-36.9%$151.19M$243.57M6.42200BMEABiomea Fusion2.7949 of 5 stars$4.15+4.3%$39.36+848.5%-71.5%$150.39MN/A-1.0350CDTXCidara Therapeutics3.9575 of 5 stars$21.19-11.7%$32.20+52.0%+51.6%$149.33M$44.65M-0.8390STROSutro Biopharma4.3318 of 5 stars$1.79-3.2%$11.13+521.5%-50.5%$147.60M$160.96M-1.11240FATEFate Therapeutics4.6845 of 5 stars$1.29-11.9%$6.75+423.3%-72.0%$146.92M$13.45M-0.78550Short Interest ↓Gap UpTCRXTScan Therapeutics2.4298 of 5 stars$2.72-1.8%$11.25+313.6%-55.5%$145.17M$9.36M-2.57100INMBINmune Bio1.5543 of 5 stars$6.54+19.1%$20.00+205.8%-43.1%$145.01M$42,000.00-3.0010Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors Innate Pharma Competitors Adaptimmune Therapeutics Competitors Puma Biotechnology Competitors Biomea Fusion Competitors Cidara Therapeutics Competitors Sutro Biopharma Competitors Fate Therapeutics Competitors TScan Therapeutics Competitors INmune Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNYR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. (Uplisting) Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC Corp. (Uplisting) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNYR Stock Alerts